In the evolving field of cell and gene therapy (CGT), adherence to current Good Manufacturing Practice (cGMP) is crucial. This white paper provides an in-depth look at GMP requirements for equipment used in producing sterile injectable products, with a specific focus on CGT.
By adhering to GMP principles, manufacturers can mitigate risks, streamline processes, and ensure that their products meet the highest standards of safety and efficacy. Understanding and implementing these guidelines is essential for the successful development and commercialisation of innovative therapies.
To explore how 3P addresses these compliance challenges and optimises CGT manufacturing, click HERE to read the full white paper.
